MedTrace Logo

Azacitidine Compared to Conventional Chemotherapy as Consolidation of Elderly Patients With AML

NCT01794169 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2015-09-22

No results posted yet for this study

Summary

The purpose of this study is to determine whether Azacitidine consolidation is superior to standard DA consolidation treatment of acute myeloid leukemia in first complete remission in elderly patients.

Conditions

Interventions

DRUG

Azacitidine

DRUG

DA

Sponsors & Collaborators

  • Celgene Corporation

    collaborator INDUSTRY

  • Karolinska University Hospital

    lead OTHER

Principal Investigators

  • Per Bernell, M.D., Ph.D. · Karolinska University Hospital

  • Stefan Deneberg, M.D., Ph.D. · Karolinska University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2015-09-30
Completion
2018-03-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01794169 on ClinicalTrials.gov